RBC Capital Reiterates Outperform on IDEAYA Biosciences, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on IDEAYA Biosciences (NASDAQ:IDYA) and maintained a price target of $36.

December 06, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst reaffirms Outperform rating and a $36 price target for IDEAYA Biosciences, indicating a positive outlook.
The reiteration of an Outperform rating by a prominent analyst like Gregory Renza from RBC Capital typically instills confidence in investors and can lead to a positive short term impact on the stock price. The maintained price target of $36 suggests a potential upside from the current trading level, assuming the stock is trading below this target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100